Combining ferroptosis induction with anti-PD-1/PD-L1 therapy seeks to exploit complementary biology: ferroptosis can increase antigen release and DAMPs, while ICIs sustain CTL function that further downregulates tumor SLC7A11 via IFN-γ. Here, SLC7A11 is linked to neoplasm.